Cargando…
Acriflavine, a clinically approved drug, inhibits SARS-CoV-2 and other betacoronaviruses
The COVID-19 pandemic caused by SARS-CoV-2 has been socially and economically devastating. Despite an unprecedented research effort and available vaccines, effective therapeutics are still missing to limit severe disease and mortality. Using high-throughput screening, we identify acriflavine (ACF) a...
Autores principales: | Napolitano, Valeria, Dabrowska, Agnieszka, Schorpp, Kenji, Mourão, André, Barreto-Duran, Emilia, Benedyk, Malgorzata, Botwina, Pawel, Brandner, Stefanie, Bostock, Mark, Chykunova, Yuliya, Czarna, Anna, Dubin, Grzegorz, Fröhlich, Tony, Hölscher, Michael, Jedrysik, Malwina, Matsuda, Alex, Owczarek, Katarzyna, Pachota, Magdalena, Plettenburg, Oliver, Potempa, Jan, Rothenaigner, Ina, Schlauderer, Florian, Slysz, Klaudia, Szczepanski, Artur, Greve-Isdahl Mohn, Kristin, Blomberg, Bjorn, Sattler, Michael, Hadian, Kamyar, Popowicz, Grzegorz Maria, Pyrc, Krzysztof |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8751734/ https://www.ncbi.nlm.nih.gov/pubmed/35021060 http://dx.doi.org/10.1016/j.chembiol.2021.11.006 |
Ejemplares similares
-
Vaccination versus SARS-CoV-2 Omicron: three vaccine doses win the battle
por: Popowicz, Grzegorz Maria, et al.
Publicado: (2022) -
Silmitasertib
(CX-4945), a Clinically Used CK2-Kinase
Inhibitor with Additional Effects on GSK3β and DYRK1A Kinases:
A Structural Perspective
por: Grygier, Przemyslaw, et al.
Publicado: (2023) -
Refolding of lid subdomain of SARS-CoV-2 nsp14 upon nsp10 interaction releases exonuclease activity
por: Czarna, Anna, et al.
Publicado: (2022) -
Characterization of SARS-CoV-2 replication complex elongation and proofreading activity
por: Jones, Alisha N., et al.
Publicado: (2022) -
Acriflavine in Otorrhœa
por: Consul, Shiam Nath
Publicado: (1925)